The high rate of side effects from oral immunotherapy in the NIH trial explains the superiority of omalizumab. A clinical ...

Project Optimus seeks to transform how doses are selected and optimised in oncology drug development. As this initiative ...

Mind Medicine (MindMed) Inc. ( NASDAQ: MNMD) Q4 2024 Earnings Conference Call March 6, 2025 8:00 AM ET Stephanie Fagan - Chief Corporate Affairs Officer Rob Barrow - CEO Dan Karlin - CMO ...

Artificial intelligence (AI) and electronic health record–based automation tools helped a safety-net health system meet performance-based readmission metrics, thereby retaining critical funding while ...

Posters presented at the Association of Cancer Care Centers opening session covered initiatives to boost clinical trial ...

Promising multiple dose PK data continue to support 4-weekly dosingFDA advice received supporting phase 2 design in HSStrong Key Opinion ...

Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history ...

A new study reveals concerning risks associated with tattoos, including higher rates of lymphoma and skin cancer.

On November 5, 2024, Adial announced the appointment of Vinay Shah as the Company’s Chief Financial Officer. Mr. Shah is an accomplished Chief Financial Officer with over 25 years of experience in the ...

Health Affairs' Senior Deputy Editor Rob Lott interviews Jihye Han of Brigham and Women's Hospital and Harvard University on ...

FORWARD-53 is an ongoing Phase 2 open-label trial of WVE-N531. Muscle biopsies are taken after 24 and 48 weeks of dosing. The ...

This article outlines the best cognitive practices for mental health which was discussed in a recent paneldiscussion.